Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT06530784
Phase
PHASE2
Status
Unknown

Conditions

  • Carcinoma, Hepatocellular

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Cryoablation — PROCEDURE
    After the completion of screening, the subjects received cryoablation treatment
  • PD-1 antibody and bevacizumab — DRUG
    Three days after cryoablation, the patients receive intravenous infusion of Tislelizumab (200mg, with 100mL of normal saline) and Bevacizumab (dose 15mg/kg, with 100mL of normal saline) .The patients will receive Tislelizumab (200 mg, with 100 mL of normal saline) and Bevacizumab (15 mg/kg, with 100 mL of normal saline) once every 3 weeks until disease progression.

Study Details

To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1/L1 antibody.

Key Dates

First listed
Jul 31, 2024
Start date
Jul 31, 2024
Status verified
Jul 2024
Primary completion
Dec 31, 2025
Completion
May 31, 2026

Study Design

Enrollment
36 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment group
    Cryoablation combined with PD-1 antibody and bevacizumab

Primary Outcome Measure

Progression-free survival [ Time Frame: Up to 2 years ]

Central Contacts

Related Studies